Pirlimycin is an analog of clindamycin that will be recommended for therapy of bovine mastitis. It has good activity against staphylococci and streptococci, the major pathogens for bovine mastitis. Five hundred and thirty bacterial isolates recovered from cows with mastitis were studied to confirm the spectrum of activity and to develop recommendations for susceptibility testing. Pirlimycin is not active against isolates ofEnterobacteriaceae, it varies in its activity against enterococci, and it is active against veterinary isolates of streptococci (MIC for 50%o of strains tested, c0.03 to 0.06 p,g/ml) and staphylococci (MIC for 50% of strains tested, 0.25 to 1.0 ,ug/ml). On the basis of levels of drug attained in the milk with recommended dosing schedules, we chose MIC breakpoints of .2 ,ug/ml for susceptibility and 24 ,ug/ml for resistance. We also recommended a disk diffusion test using a disk containing 2 ,ug/ml and breakpoints of c 12 mm for resistance and >13 mm for susceptibility.
Bovine mastitis is an economically important disease to the dairy industry, with losses estimated at more than 2 billion dollars a year in the United States (3) . At least 135 different species of microorganisms have been implicated in bovine mastitis, but the majority of these infections are caused by staphylococci and streptococci (12) . Antimicrobial therapy for both lactational and dry cows is important in reducing the level of mastitis in dairy herds (3) .
Antimicrobial susceptibility testing of the causal pathogens is considered an important factor in selecting the most appropriate therapeutic agent for therapy of mastitis, but no standard criteria for testing the organisms that cause bovine mastitis exist. Current criteria used for categorizing organisms as resistant or susceptible are usually based on the standard recommendations developed by the National Committee for Clinical Laboratory Standards for organisms and antimicrobial agents used for therapy of human diseases (5-7), e.g., regression statistics, population distribution, and clinical response, methods which require knowledge of the levels of the agent in tissue following usual therapy. With rare exceptions, the National Committee for Clinical Laboratory Standards breakpoints are based upon concentrations of the antimicrobial agent that are achieved in the blood of the average patient who receives the usual dosage by either an intravenous or an oral route. The exceptions are the rare antimicrobial agents for which significant levels of drug accumulate in the urine but not in blood or tissue. In the therapy of bovine mastitis, the drugs are infused directly into the udder, making concentrations in milk the major param and it has potent activity against many gram-positive cocci, including staphylococci and streptococci (2, 13) . The use of pirlimycin would be facilitated if antimicrobial susceptibility tests could be performed on the isolates from mastitis specimens with breakpoints developed specifically for mastitis therapy. The purposes of this study were to determine the spectrum of activity of pirlimycin against bacteria isolated from cows with mastitis and to develop breakpoints for determining categories of susceptibility by disk diffusion tests with pirlimycin when tested against mastitis pathogens.
MATERIALS AND METHODS
Bacteria. Except for the human isolates, the strains used in this study were relatively recent isolates (from 1986 to 1991) from bovine intramammary infections and had been stored on 3-mm-diameter glass beads at -70°C in Trypticase soy broth (BBL Microbiology Systems, Cockeysville, Md.) in the laboratories of the Upjohn Company. Some of the staphylococci tested were human isolates that were added because of their resistance, e.g., to methicillin, and had been stored in blood at -70°C or colder temperatures. The strains were subcultured onto appropriate media and sent to the Institutes for Microbiology Research, where they were subcultured at least two times prior to being tested. The following species (numbers of strains) were included in the study: Enterobacter aerogenes (1) only a limited number of isolates were tested with the 0.25-, 0.5-, and 1.0-,ug disks. Commercially acquired clindamycin disks (2 p,g) were also tested. Staphylococci were tested for 3-lactamase production by the nitrocefin test (Cefinase; BBL Microbiology Systems) and for methicillin resistance by the oxacillin screen test (11) . Prior to being tested for ,B-lactamase production, the isolates had been induced with oxacillin by growing the strain on a blood agar plate with an oxacillin disk and testing growth near the disk or the edge of the zone of inhibition (10) . Assay of pirlimycin in milk. The concentrations of pirlimycin in milk were determined in two studies, and the data were supplied by the Upjohn Company. In those studies, two 50-mg doses of pirlimycin were administered at 0 and 24 h into each mammary gland quarter. Samples of milk were assayed for pirlimycin at 0, 12, 24, 36, 48, 60, and 72 h. The assay method used was a modified agar diffusion bioassay (1) in which the indicator organism (Micrococcus luteus ATCC 9341) was sensitized with a highly basic (pH 8.5) medium. Milk samples were centrifuged at 3,000 x g at 4°C for 15 min to separate the fat from the milk. The final pH of the decanted sample was adjusted to 8.5 with 1 N NaOH. A 100-pl aliquot of the sample was added to wells cut in agar plates (Difco antibiotic medium 11; pH 8.5) seeded with the indicator organism. Zones of inhibition were measured and compared with a standard curve obtained with known concentrations of pirlimycin. The assay was sensitive to 0.02 ,ug of pirlimycin per ml.
Breakpoint determination. MICs and zone diameters for 2-, 4-, 8-, and 16-,ug disks for each isolate were plotted as scattergrams (only data for 2-,ug disks are shown). The MIC breakpoint selected was based on the concentration of pirlimycin in milk over 2 days following daily doses of 50 mg per dose per mammary gland quarter. A combination of regression analysis (excluding off-scale values for MICs and 6-mm-diameter zones) and error rate bounding was used to determine the disk diffusion breakpoints (4-7).
RESULTS
Although several disk masses were used in the study (data not shown), we chose the 2-,ug disk because it yielded desirable zone diameters that generally were 15 to 30 mm for susceptible strains (generally the more reproducible range) and a regression line with a slope that permitted adequate discrimination between susceptible and resistant strains. This is the same concentration that was selected for clindamycin, of which pirlimycin is an analog, but that was not a major selection criterion (2) .
The concentrations of pirlimycin in milk when given at 2 doses of 50 mg per mammary gland quarter 24 h apart are shown in Table 1 . The levels at 12 and 36 h were 8.7 and 7.52 ug/ml, and for most of the 48 h the amount of drug appears to exceed 2 p,g/ml (8a); this concentration was chosen as the susceptible MIC breakpoint. Thus, organisms for which MICs were c2 p,g/ml would be categorized as susceptible.
The scattergram and linear regression line for the pirlimy- moved, there would be one very major error (false susceptibility) and two major errors (false resistance).
The activities of pirlimycin and clindamycin against these selected mastitis and human isolates, as determined by MICs, are shown in Table 2 . Pirlimycin, like clindamycin, had little activity against the gram-negative isolates, as indicated by MICs of >32 ig/ml and zone diameters of 6 mm (no zone). Pirlimycin and clindamycin were, on the other hand, active against the gram-positive cocci tested in this study, although less so for E. faecalis. Although some isolates of S. aureus, S. epidermidis, and the other coagulase-negative staphylococcal species were resistant (MIC, 24 ,ug/ml), MICs for the susceptible isolates generally were .0.5 ,ug/ml. There were also some resistant isolates of streptococci, but the MICs for susceptible strains were generally lower than those for the staphylococcal isolates, e.g., c0.03 p,g/ml. The E. faecalis isolates were less susceptible to these drugs than were staphylococci and streptococci. The MICs of pirlimycin for E. faecalis were mostly 1 and 2 jig/ml, although MICs for 6 of the 22 isolates were c0.5 ,ug/ml. For most of these enterococcal isolates, pirlimycin MICs were two to four times lower than the MICs of clindamycin. The zone sizes also reflect the lesser activities of both agents for E. faecalis; those isolates for which MICs were .0.5 ,g/ml had pirlimycin and clindamycin zone sizes of 6 to 10 mm, while those for which MICs were <0.5 ,ug/ml had zone diameters indicating susceptibility (>12 mm).
The zone diameters for the 2-,ug pirlimycin disk for the species tested in this study ranged from 6 (no zone) to 31 mm, as can be seen in Fig. 2 Fig. 2 . These data show that one could use clindamycin zones and the same breakpoint recommended for pirlimycin (>13 mm equals susceptibility) to predict for pirlimycin susceptibility. The five strains that were very major errors (with numbers of isolates in parentheses) were S. uberis (1), S. epidennidis (2), S. aureus (1) , and S. agalactiae (1) .
The ,-lactamase and methicillin susceptibility results for the staphylococcal species are shown in Table 3 . All of the species had significant percentages of strains that produced ,B-lactamase, ranging from 27.6% for S. hyicus to 84% for S. epidermidis. The susceptibilities to methicillin of these staphylococci varied and were largely influenced by the human isolates. All isolates of S. chromogenes and S. xylosus and 93.1% of S. hyicus isolates were susceptible to methicillin. The overall methicillin resistance rates were 6.9% for S. hyicus, 29.1% for S. epidermidis, and 30.8% for S. aureus, with most of the methicillin-resistant S. epidermidis and S. aureus isolates being human isolates. Only 3.9% of the mastitis S. aureus and 7.4% of the mastitis S. epidermidis isolates were resistant to methicillin. All strains but one (95.8%) of S. aureus that were resistant to methicillin were also resistant to pirlimycin, and 73.9% of the methicillin-resistant S. epidennidis isolates were also resistant to pirlimycin. The two methicillin-resistant strains of S. hyicus were susceptible to pirlimycin. 
DISCUSSION
The breakpoints that have been used for determining the categories of susceptibility (susceptible, moderately susceptible, intermediate, and resistant) for drugs used in the therapy of infections in animals have been those breakpoints used for therapy of infections in humans (5) (6) (7) . Among the problems with using these breakpoints in animal medicine are that dosages are different, the pharmacokinetics for these drugs are different in different host animals, and the pathogens are often different from those in humans. In almost all cases for antimicrobial agents in human microbiology, breakpoints are based on concentrations of the drug attained in the blood of average patients with the usual dosage of the drug, although it is recognized that the level of the drug in infected tissues may not be the same as in that blood and that the levels attained in different individuals may vary significantly. There are, however, a few antimicrobial agents used for human infections for which the breakpoints are based solely on levels in urine, e.g., nitrofurantoin and nalidixic acid, drugs which yield no significant levels in blood but are concentrated in the urine. Thus, these drugs are used only for urinary tract infections (5, 6) .
The latter situation is somewhat analogous to that which exists in the therapy of bovine mastitis in that the antimicrobial agents are infused directly into the individual quarters of the udder, yielding concentrations of the drugs in milk that are dose dependent but that also will be removed during the milking process and that are unrelated to concentrations in blood. Therefore, we chose to use levels in milk achieved by intramammary infusion of pirlimycin into the udder to determine the disk diffusion breakpoints for susceptible and resistant categories. On the basis of the data shown in Fig. 1 , we chose 2 ,ug/ml as the MIC breakpoint, i.e., any organism for which an MIC is 52 ,ug/ml is, by definition, susceptible to pirlimycin, whereas an organism for which an MIC is >2 ,ug/ml is resistant to pirlimycin. The subsequent decision about a disk diffusion breakpoint had to be based on this MIC breakpoint. As shown in Fig. 2 , breakpoints of <12 mm for resistance and >13 mm for susceptibility correctly predict the category of susceptibility for almost all strains. The number of very major errors (false susceptibility) is well within the rates that have been suggested as acceptable (10) . Although the number of major errors (false resistance) is larger, it is also within the accepted range (10) .
The role that milk might play in the activity of the antimicrobial agent has not been considered in determining this breakpoint. There are some indications that milk may adversely affect the activities of some antimicrobial agents. For example, Owens In summary, pirlimycin is a new analog of clindamycin that is being proposed for therapy of bovine mastitis. It has marked activity against staphylococci and streptococci, the major pathogens for mastitis. A disk diffusion test using a 2-,ug disk and breakpoints of <12 mm for resistance and .13 mm for susceptibility will discriminate between susceptible ANTIMICROB. AGENTS CHEMOTHER. and resistant strains judged by MIC breakpoints of 52 ,g/ml for susceptibility and .4 ,ug/ml for resistance.
